Antitumor effect of macrolides - Erythromycin and roxithromycin in B16 melanoma-transplanted mice

Pharmacological Reports

Volumn 59, Issue SUPPL. 1, 2007, Pages 269-274

  Chlebda, Ewa ^a   Merwid Lad, Anna ^a   Szumny, Dorota ^a   Trocha, Małgorzata ^a   Fereniec Gołebiewska, Lidia ^a   Gebarowska, Elzbieta ^a   Kowalski, Przemysław ^a   Szelag, Adam ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Erythromycin; Macrolides; Mouse B16 melanoma; Roxithromycin

Indexed keywords

ERYTHROMYCIN; MACROLIDE; ROXITHROMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CANCER TRANSPLANTATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; FEMALE; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN;

EID: 38049121446     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Alvarez-Elcoro S, Enzler MJ: The macrolides: erythromycin, clarithromycin, and azithromycin. Mayo Clinic Proc, 1999, 74, 613-634.
2. Baranczewski P, Stanczak A, Sundberg K, Svensson R, Wallin A, Jansson J, Garberg P, Postlind H: Introduction to in vitro estimation of metabolic stability and drug interactions of new chemical entities in drug discovery and development. Pharmacol Rep, 2006, 58, 453-472.
3. Culic O, Erakovic V, Parnham MJ: Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol. 2001, 19, 209-229.
4. de Brand F, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N: Malignant melanoma. Crit Rev Oncol Hematol, 2003, 47, 35-63.
5. Hamada K, Kita E, Sawaki M, Mikasa K, Narita N: Antitumor effect of erythromycin in mice. Chemotherapy, 1995, 41, 59-69.
6. Hamada K, Mikasa K, Yunou Y, Kurioka T, Majima T, Narita N, Kita E: Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy, 2000, 46, 49-61.
7. Majima T: A promising tumor dormancy therapy using a 14-membered macrolide for patients with unresectable non-small cell lung cancer: basis and clinical analysis. J Nara Med Assioc, 2000, 51, 304-320.
8. Mikasa K, Sawaki M, Kita E, Hamada K, Konishi M, Maeda K, Teramoto S et al.: Clarithromycin in the long-term treament of primary lung cancer: possibility of clarithromycin as a biological response modifier. Chemotherapy, 1995, 42, 1293-1298.
9. Rozalski M, Mirowski M, Balcerczak E, Krajewska U, Mlynarski W, Wierzbicki R: Induction of caspase 3 activity, bcl-2 bax and p65 gene expression modulation in human acute promyelocytic leukemia HL-60 cells by doxorubicin with amifostine. Pharmacol Rep, 2005, 57, 360-366.
10. Sakamoto M, Mikasa K, Majima T, Hamada K, Konishi M, Maeda K, Kita E et al.: Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer. Chemotherapy, 2001, 47, 444-451.
11. Sassa K, Mizushima Y, Fujishita T, Oosaki R, Kobayashi M: Therapeutic effect of clarithromycin on a transplanted tumor in rats. Antimicrob Agents Chemother, 1999, 43, 67-72.
12. Sassa K, Mizushima Y, Kobayashi M: Differential modulatory effects of clarithromycin on the production of cytokines by a tumor. Antimicrob Agents Chemother, 1999, 43, 2787-2789.
13. Sausville EA, Hollingshead M: Mouse models in cancer drug discovery and development. In: Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Ed. Figg WD, McLeod HL, Humana Press, Totowa, 2004, 45-56.
14. Sauter C, Blum S: Regression of lung lesions in Hodgkin's disease by antibiotics: case report and hypothesis on the etiology of Hodgkin's disease. Am J Clin Oncol, 2003, 26, 92-94.
15. Tsutsumi M, Kitada H, Shiraiwa K, Takahama M, Tsujiuchi T, Sakitani H, Sasaki Y et al.: Inhibitory effects of combined administration of antibiotics and anti-inflammatory drugs on lung tumor development initiated by N-nitroso-bis(2-hydroxypropyl) amine in rats. Carcinogenesis, 2000, 21, 251-256.
16. Wang L, Kitaichi K, Hui CS, Takagi K, Takagi K, Sakai M, Yokogawa K et al.: Reversal of anticancer drug resistance by macrolide antibiotics in vitro and in vivo. Clin Exp Pharmacol Physiol, 2000, 27, 587-593.
17. Williams JD: Non-antimicrobial activities of macrolides. Int J Antimicrob Agents, 2001, 18, Suppl 1, S89-91.
18. Yatsunami J, Fukuno, Y, Nagata M, Tominaga M, Aoki S, Tsuruta N, Kawashima M et al.: Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells. Clin Exp Metastasis, 1999, 17, 361-367.
19. Yatsunami J, Fukuno, Y, Nagata M, Tsuruta N, Aoki S, Tominaga M, Kawashima M et al.: Roxithromycin and clarithromycin, 14-membered ring macrolides, potentiate the antitumor activity of cytotoxic agents against mouse B16 melanoma cells. Cancer Lett, 1999, 147, 17-24.
20. Yatsunami J, Tsuruta N, Fukuno, Y, Kawashima M, Taniguchi S, Hayashi S: Inhibitory effects of roxithromycin on tumor angiogenesis, growth and metastasis of mouse B16 melanoma cells. Clin Exp Metastasis, 1999, 17, 119-124.
21. Yatsunami J, Tsuruta N, Hara N, Hayashi S: Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic. Cancer Lett, 1998, 131, 137-143.
22. Yatsunami J, Turuta N, Wakamatsu K, Hara N, Hayashi S: Clarithromycin is a potent inhibitor of tumor-induced angiogenesis. Res Exp Med (Berl), 1997, 197, 189-197.